Workflow
银轮股份(002126) - 2019 Q1 - 季度财报
YINLUNYINLUN(SZ:002126)2019-04-26 16:00

Financial Performance - The company's operating revenue for Q1 2019 was ¥1,388,604,575.34, representing a 15.25% increase compared to ¥1,204,850,065.52 in the same period last year [9] - Net profit attributable to shareholders was ¥108,914,529.07, up 6.42% from ¥102,345,009.35 year-on-year [9] - The net profit after deducting non-recurring gains and losses decreased by 19.91% to ¥76,835,017.15 from ¥95,931,961.55 in the previous year [9] - Basic earnings per share rose by 7.69% to ¥0.14 from ¥0.13 in the same period last year [9] - The company's total comprehensive income for the current period was ¥113,879,902.41, compared to ¥85,297,258.21 in the previous period, indicating a growth of 33.59% [59] - The company reported a total profit of ¥139,544,398.89, an increase of 5.06% from ¥131,874,026.85 in the previous period [55] Cash Flow - The net cash flow from operating activities was negative at -¥5,475,532.39, a decline of 114.93% compared to ¥36,669,743.49 in the same period last year [9] - Cash inflow from operating activities totaled ¥907,581,264.68, up from ¥816,601,602.41 in the previous period, showing a growth of approximately 11% [71] - Cash inflow from investment activities was ¥481,855,254.35, down from ¥630,877,713.03, representing a decrease of about 24% [74] - Net cash flow from investment activities was -¥222,101,507.77, compared to -¥66,515,467.73 in the previous period, indicating a worsening investment position [74] - Cash inflow from financing activities was ¥655,370,756.65, a decrease from ¥892,363,350.00, reflecting a reduction of approximately 26% [74] - Net cash flow from financing activities improved to ¥163,757,207.60 from ¥116,022,610.49, indicating better financing management [74] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,990,592,840.29, an increase of 1.68% from ¥7,858,823,185.48 at the end of the previous year [9] - The total liabilities increased to CNY 3,954,162,923.41, up from CNY 3,761,910,266.69, representing a growth of approximately 5.1% [38] - The total owner's equity decreased to CNY 4,036,429,916.88 from CNY 4,096,912,918.79, indicating a decline of about 1.5% [41] - The total current liabilities amounted to CNY 2,477,341,196.59, up from CNY 2,326,920,517.22, which is an increase of approximately 6.5% [48] - Long-term borrowings increased to CNY 158,000,000.00 from CNY 100,000,000.00, representing a growth of 58% [48] Expenses - Total operating costs amounted to ¥1,288,618,337.20, up 19.16% from ¥1,081,794,543.72 in the prior period [52] - Sales expenses increased by 44.99% year-on-year, mainly due to the consolidation of Jiangsu Weiyi and Jiangsu Langxin [20] - Management expenses rose by 35.43% year-on-year, primarily attributed to the inclusion of Jiangsu Weiyi and Jiangsu Langxin in the consolidation [20] - Research and development expenses rose to ¥51,546,563.52, up 15.00% from ¥44,655,573.13 in the previous period [52] - The financial expenses for the current period were ¥24,694,103.99, an increase of 20.00% from ¥20,485,687.54 in the previous period [52] Other Income and Investments - Other income increased by 667.32% year-on-year, mainly due to a rise in government subsidies received [20] - Investment income grew by 41.69% year-on-year, primarily from the sale of part of the shares in Shengda Bio [20] - The company received government subsidies amounting to ¥16,815,982.21 during the reporting period [9] - Investment income for the current period was ¥9,070,784.43, up 41.67% from ¥6,401,839.38 in the previous period [52] Shareholder Information - The top shareholder, Tiantai Yinlun Industrial Development Co., Ltd., holds 10.04% of the shares, with a total of 80,444,000 shares [13] - The company repurchased a total of 3,726,860 shares, accounting for 0.4652% of the total share capital, with a total transaction amount of approximately 29.98 million yuan [21] Changes in Financial Standards - The company has implemented new financial and revenue recognition standards, impacting the financial statements [82] - The company implemented new financial instrument standards starting January 1, 2019, affecting financial statement presentation [97]